{"product_id":"alnylam-bcg-matrix","title":"Alnylam Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlnylam’s BCG Matrix snapshot shows which RNAi assets are sprinting ahead and which need tougher choices — a quick way to see Stars, Cash Cows, Question Marks, and Dogs at a glance. This preview sketches competitive dynamics, but the full BCG Matrix breaks each product into quadrant-level detail, data-driven recommendations, and a clear capital-allocation roadmap. Buy the complete report to get editable Word and Excel files, actionable strategy, and a ready-to-present view you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmvuttra (vutrisiran)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmvuttra (vutrisiran) was FDA approved for hATTR polyneuropathy on 22 September 2022 and offers a subcutaneous dose every three months versus IV patisiran every three weeks, giving a clear convenience edge that drove rapid clinical uptake. It holds a strong share within the still-expanding hereditary ATTR polyneuropathy market. Alnylam continues to invest in launch activities, centers of excellence, and real‑world evidence to defend and extend the lead. If growth sustains, Amvuttra is positioned to graduate to cash cow status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ehATTR Franchise Lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam effectively owns the RNAi segment in hATTR with ONPATTRO (FDA approval 2018) and AMVUTTRA (FDA approval 2022), setting the pace on outcomes and access across neurology and cardiology. Category growth and brand-switching tailwinds favor further uptake as clinicians consolidate on RNAi efficacy and dosing convenience. Prioritize investment to lock in cardiology co-management and expand global penetration through hub-and-spoke models. Protect switching dynamics by building payer-friendly, low-friction pathways and real-world evidence generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGivlaari Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGivlaari momentum is driven by rising AHP patient identification; symptomatic AHP prevalence is roughly 1 per 100,000 and screening yields are improving. Givlaari, FDA-approved in 2019, showed a 74% reduction in annualized attack rate in ENVISION, underpinning durable access. Continue expanding diagnostic funnels and center coverage to capture untreated patients. Scale adherence programs to convert early starts into repeat dosing and predictable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOxlumo Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrimary hyperoxaluria type 1 affects ~1–3 per million and is underdiagnosed; Oxlumo (lumasiran) approved by FDA in Nov 2020 shows robust reduction in urinary oxalate, driving specialist pull and referral growth; expanding newborn and genetic screening can enlarge the treatable pool; tighten supply chain and hub services to shorten time-to-start and improve adherence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePH1 prevalence: 1–3\/million\u003c\/li\u003e\n\u003cli\u003eFDA approval: Nov 2020\u003c\/li\u003e\n\u003cli\u003eDriver: strong efficacy → specialist demand\u003c\/li\u003e\n\u003cli\u003eActions: screening expansion; supply\/hub optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalNAc RNAi Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGalNAc RNAi Edge: best‑in‑class hepatic delivery widely recognized—Alnylam’s RNAi portfolio includes Onpattro (patisiran, FDA 2018), Givlaari (givosiran, FDA 2019) and Amvuttra (vutrisiran, FDA 2022), demonstrating clinical and commercial validation; continued chemistry iterations and publications expand tissue reach and compound the lead as RNAi adoption grows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTech lead: GalNAc hepatic targeting\u003c\/li\u003e\n\u003cli\u003eValidated: 3 Alnylam RNAi approvals by 2024\u003c\/li\u003e\n\u003cli\u003eStrategy: publish, iterate chemistry, broaden tissues\u003c\/li\u003e\n\u003cli\u003eOutcome: leadership → potential category dominance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalNAc RNAi leaders drive high-growth rare-disease franchises; prioritize launches and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam’s Stars (Amvuttra, Oxlumo, Givlaari) show high growth and leading shares in expanding rare-disease niches, driven by GalNAc RNAi advantage and strong clinical uptake in 2024. Continued launch investment, real‑world evidence, and diagnostic expansion are prioritized to sustain growth and transition to cash cows. Protect access via payer pathways and hub optimization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Rev ($M)\u003c\/th\u003e\n\u003cth\u003eMarket CAGR\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmvuttra\u003c\/td\u003e\n\u003ctd\u003e~600\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOxlumo\u003c\/td\u003e\n\u003ctd\u003e~250\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Alnylam’s portfolio with quadrant insights and invest\/hold\/divest guidance\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Alnylam BCG Matrix that clarifies portfolio gaps, highlights resource shifts, and simplifies C-suite decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnpattro Legacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOnpattro legacy remains a cash cow for Alnylam in 2024, driven by an established patient base and durable ex-US uptake that continues to generate recurring infusion revenue. Lower promotional intensity is possible as care pathways and specialist networks are mature. Focus is on optimizing gross-to-net and infusion operations to maximize free cash flow. Harvest strategy must manage cannibalization risk from subQ Amvuttra. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeqvio Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeqvio royalties supply Alnylam a rising, high‑margin PCSK9‑siRNA cash stream with minimal opex drag; 2024 Leqvio global sales reached about $2.0bn, underpinning growing royalty receipts. Predictable royalties contribute steady free cash flow and margin expansion, funding R\u0026amp;D and pipeline bets. Alnylam supports partner uptake via post‑hoc data releases and policy advocacy to sustain volume and pricing, treating royalties as funding fuel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Tail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRare Disease Tail functions as a cash cow: stable, high‑value patients often generate \u0026gt;$100,000 per patient per year with multi‑year to lifelong durations, creating predictable revenue streams. Mature accounts require modest field effort and lower churn, letting SG\u0026amp;A per patient fall materially. Incremental infrastructure tweaks commonly lift margins 200–400 basis points, so milk the base while maintaining gold‑standard support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeographic scale: by 2024 Alnylam has established commercial access across the EU and Japan, with distribution and pricing know‑how streamlined to reduce launch friction and reimbursement timelines.\u003c\/p\u003e\n\u003cp\u003eLow incremental cost per additional patient and repeatable operations improve cash generation; label harmonization and participating in tenders further compress marginal cost and accelerate uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEU\/Japan commercial presence (2024)\u003c\/li\u003e\n\u003cli\u003eLow incremental cost per patient — operational repeatability\u003c\/li\u003e\n\u003cli\u003eLabel harmonization + tenders boost margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing leverage at Alnylam drives lower COGS through process know‑how and strict CMC discipline, contributing to improved gross margin versus earlier years; 2024 revenue reached roughly $3.2 billion, supporting scale benefits.\u003c\/p\u003e\n\u003cp\u003eShared platforms spread fixed costs across RNAi programs, and continuous improvement efforts have steadily boosted yield and margin, turning manufacturing into a quiet, dependable cash enhancer.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMC discipline reduces per-unit COGS\u003c\/li\u003e\n\u003cli\u003eShared platforms amortize fixed costs\u003c\/li\u003e\n\u003cli\u003eContinuous improvement increases yield\/margin\u003c\/li\u003e\n\u003cli\u003e2024 revenue ~ $3.2B supports manufacturing scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e$2.0B\u003c\/strong\u003e royalties \u0026amp; \u0026gt;$100k\/pt margins power \u003cstrong\u003e$3.2B\u003c\/strong\u003e 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnpattro remains a 2024 cash cow with steady infusion revenue; Amvuttra cannibalization must be managed. Leqvio royalties (~$2.0bn global sales 2024) provide high‑margin, predictable cash. Rare disease portfolios yield \u0026gt;$100k\/patient\/year with low SG\u0026amp;A. Manufacturing scale and 2024 revenue ~ $3.2B compress COGS and boost free cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeqvio sales\u003c\/td\u003e\n\u003ctd\u003e$2.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer‑patient RD\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAlnylam BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing is the exact, final BCG Matrix you’ll receive after purchase. No watermarks or demo content — just a fully formatted, analysis-ready report crafted by strategy experts. Buy once and download immediately for editing, printing, or presenting to clients and teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIV Patisiran Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIV patisiran (Onpattro) requires weight-based IV infusions every 3 weeks for hATTR polyneuropathy, which creates significant infusion burden and drives switching to subcutaneous alternatives like vutrisiran (approved 2022) dosed every 3 months. The high administration overhead yields modest incremental revenue versus lower-burden rivals, making growth hard to achieve through marketing alone. Manage decline and redeploy field time to higher-growth subQ assets and specialty indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaxed Micro‑Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltra‑niche cohorts for Alnylam products are essentially fully penetrated, with new patient flow at trickle level and commercial starts showing minimal growth in 2024. Chasing the last few starts is expensive given high acquisition and reimbursement costs per patient. Recommendation: hold accounts and avoid over‑investing in marginal uptake opportunities to protect margin and cash deployment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder Delivery IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOlder delivery IP at Alnylam relies on legacy chemistries that no longer differentiate, representing a shrinking strategic footprint as the company reported $2.34B product revenue in 2023 and shifted R\u0026amp;D toward GalNAc and next‑gen platforms. Maintenance costs persist without strategic upside, and these assets are competitively outclassed by newer LNP and GalNAc approaches. Sunset legacy IP and reallocate resources to next‑gen delivery to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon‑Core Infectious\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDogs: \u003c\/p\u003e\n\u003ch3\u003eNon‑Core Infectious\u003c\/h3\u003e sits outside Alnylam’s 2024 near‑term sweet spot of hepatic genetic and cardio‑metabolic programs; infectious assets account for a single‑digit percent of the pipeline. Clinical complexity and tougher payer pathways curb commercial upside; Alnylam’s 2024 revenue ~$2.2B and \u0026gt;$1B R\u0026amp;D budget remain focused elsewhere. De‑prioritize unless a partner assumes development and commercialization.\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share: single‑digit % of pipeline\u003c\/li\u003e\n\u003cli\u003eLow growth: limited near‑term commercial potential\u003c\/li\u003e\n\u003cli\u003eClinical\/payer risk: high\u003c\/li\u003e\n\u003cli\u003eAction: deprioritize unless partnered\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOverlapping Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam in 2024 has 4 marketed RNAi products and over 20 pipeline programs; several internal programs compete for overlapping rare-disease pools, many with patient populations in the low thousands, creating portfolio clutter that dilutes clinical and commercial focus. Parallel spend across similar targets yields marginal incremental returns versus consolidated programs; prune or merge to reallocate capital to higher-return assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 marketed products (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20 pipeline programs (2024)\u003c\/li\u003e\n\u003cli\u003eMany targets: patient pools often low-thousands\u003c\/li\u003e\n\u003cli\u003ePrune\/merge to free capital and improve ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeprioritize infectious assets: \u003cstrong\u003esingle-digit %\u003c\/strong\u003e of pipeline; partner to shift cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: non‑core infectious assets represent single‑digit % of pipeline in 2024 and carry high clinical\/payer risk; Alnylam reported ~$2.2B product revenue and \u0026gt;$1B R\u0026amp;D in 2024, focusing on hepatic GalNAc programs. Limited growth prospects; deprioritize unless partnered to transfer cost and risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e~$2.2B\u003c\/td\u003e\n\u003ctd\u003eReallocate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B\u003c\/td\u003e\n\u003ctd\u003eProtect core\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfectious share\u003c\/td\u003e\n\u003ctd\u003eSingle‑digit %\u003c\/td\u003e\n\u003ctd\u003eDeprioritize\/partner\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZilebesiran (HTN)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZilebesiran targets a massive market—~1.3 billion adults with hypertension and a global antihypertensive market ~35 billion USD (2024)—with clear unmet need in adherence and true 24\/7 control as control rates are \u0026lt;20% globally. Early data are promising but commercial share is zero today; development will be capital intensive with payer proof of durable outcomes required. Strategy: invest heavily in outcomes\/durability or partner for scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS RNAi Push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCNS RNAi Push targets new routes and new biology with high upside if delivery hurdles fall; by 2024 six siRNA therapies had FDA approval, underscoring platform potential. Technical risk remains meaningful given blood‑brain barrier challenges and lack of approved CNS siRNA to date. If tissue targeting clicks, program valuation could materially reset. Stage‑gate funding is tied to biomarker-driven go\/no‑go milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcular RNAi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcular RNAi targets multi‑billion dollar retinal franchises (market \u0026gt;US$10B in 2024) crowded by incumbents Roche, Novartis and Regeneron, so differentiation must be dosing ease and durability. Early traction will hinge on clean ocular safety; invest selectively and fast‑follow pivotal readouts and biomarker data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCemdisiran Combo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCemdisiran combo sits as a Question Mark: complement diseases have clear biology and established premium pricing—eculizumab\/ravulizumab range roughly $450k–$600k\/year—so combos can carve defensible niches by improving durability or dosing. Success requires head‑to‑head or compelling real‑world evidence to shift prescriber economics. Back it conditional on visible partner momentum and clear POC.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddressable market: rare complement diseases (aHUS\/PNH incidence ~0.5–2\/million)\u003c\/li\u003e\n\u003cli\u003ePricing leverage: ~$450k–$600k\/yr for current C5 inhibitors\u003c\/li\u003e\n\u003cli\u003eSuccess trigger: H2H or RWE\u003c\/li\u003e\n\u003cli\u003eDecision: partner momentum required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Cardio‑Metabolic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNew Cardio‑Metabolic is a Question Mark: liver‑targeted RNAi can unlock large chronic markets (NAFLD\/NASH prevalence ~25% globally in 2024), but competition is intense and payers demand hard outcomes; early biomarker wins (ALT, fibrosis scores) can rapidly translate to share and valuation inflection; fund winners, exit laggards quickly.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eMarket opportunity: NAFLD ~25% prevalence (2024)\u003c\/li\u003e\n\u003cli\u003eClinical focus: biomarker-driven approval pathways\u003c\/li\u003e\n\u003cli\u003eCommercial: outcomes determine payer access\u003c\/li\u003e\n\u003cli\u003eStrategy: concentrate capital on rapid proof-of-concept\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHypertension \u003cstrong\u003e~1.3B\u003c\/strong\u003e\/\u003cstrong\u003e$35B\u003c\/strong\u003e; NAFLD \u003cstrong\u003e~25%\u003c\/strong\u003e — upside if durable\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: large addressable markets but high development\/commercial risk — hypertension (Zilebesiran: ~1.3B adults, antihypertensive market ~$35B 2024, control \u0026lt;20%) and NAFLD (~25% prevalence 2024) offer upside if durability\/outcomes proven; CNS\/ocular RNAi show platform potential (six siRNA FDA approvals by 2024) but delivery\/safety risks; cemdisiran combos need H2H\/RWE vs C5 inhibitors (~$450k–$600k\/yr).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMarket size\/metric (2024)\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eDecision\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZilebesiran\u003c\/td\u003e\n\u003ctd\u003e~1.3B adults; $35B\u003c\/td\u003e\n\u003ctd\u003econtrol \u0026lt;20%\u003c\/td\u003e\n\u003ctd\u003eInvest if outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS RNAi\u003c\/td\u003e\n\u003ctd\u003ePlatform; 6 approvals\u003c\/td\u003e\n\u003ctd\u003eBBB delivery\u003c\/td\u003e\n\u003ctd\u003eStage‑gate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcular\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$10B\u003c\/td\u003e\n\u003ctd\u003eocular safety\u003c\/td\u003e\n\u003ctd\u003eSelective\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCemdisiran\u003c\/td\u003e\n\u003ctd\u003erare C5 diseases\u003c\/td\u003e\n\u003ctd\u003e$450k–$600k\/yr\u003c\/td\u003e\n\u003ctd\u003ePartner conditional\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardio‑Metabolic\u003c\/td\u003e\n\u003ctd\u003eNAFLD ~25%\u003c\/td\u003e\n\u003ctd\u003ebiomarkers→outcomes\u003c\/td\u003e\n\u003ctd\u003eRapid POC only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097874272604,"sku":"alnylam-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/alnylam-bcg-matrix.png?v=1781787980","url":"https:\/\/pestel-analysis.com\/products\/alnylam-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}